| Hepatitis B Virus Vaccine | Selma TOSUN | 37–46 |
| The Evaluation of HBV-DNA Levels In Patients who Had Lost Hbsag After Recovery From Hepatitis B Virus Infection | Vicdan MOTOR KÖKSALDI,Aysel ÇELİKBAŞ KOCAGÜL,Nurcan BAYKAM,Şebnem GÖK EREN,Başak DOKUZOĞUZ | 47–51 |
| Determination of Liver Disease in Incidentally Detected HBsAg Positives | Hilal DAĞTEKİN,Fehmi TABAK,Bilgül METE,Abdullah SONSUZ,Ali MERT,Reşat ÖZARAS,Neşe SALTOĞLU,Recep ÖZTÜRK | 52–56 |
| HBsAg Seroprevalence of Porters Admitted to Public Health Laboratory | Raike KALAYCI,Harun BALCI,YUSUF AKDEMİR,Mustafa ALTINDİŞ | 57–59 |
| Relationship between HBV-DNA Level and Treatment Success in HBeAg Negative Patients Treated with Pegylated Interferone | Ertuğrul GÜÇLÜ,NAZAN TUNA,Mehmet YAHYAOĞLU,Oğuz KARABAY | 60–63 |
| Screening Indicators of Hepatitis A, Hepatitis B, Hepatitis C and HIV infections in Prisoners | Elçin BALCI,Kamuran TÜRKER,Vesile ŞENOL,Osman GÜNAY | 64–67 |
| The Evaluation of Pegylated Interferon Therapy in Patients with Chronic Hepatitis Delta | AYŞE ALBAYRAK,Muharrem COŞKUN,AHMET UYANIKOĞLU,Yasin BAYIR,Havva YILMAZ,Yunus İlyas KİBAR,Ahmet TAY,Fatih ALBAYRAK | 68–70 |
| Antibody Response to Hepatitis B Vaccination in Isolated Anti-Hbc IgG Positive Cases | ESRA KAZAK,Emel YILMAZ,Reşit MISTIK,Halis AKALIN,Semra AKGÖZ,Güher GÖRAL | 71–75 |
| HBsAg, Anti-HCV and Anti-HIV Seroprevalence of the patients apply to Kars Public Hospital | YELİZ ÇETİNKOL | 76–80 |